Clinical trials
Drug Resistance clinical trials
Below are recruiting drug resistance clinical trials, each written for real people, not researchers. We’re tracking 122 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02531880RecruitingPhase 1
MRI test of a brain barrier issue in hard-to-treat epilepsy
This early-phase study uses a special MRI approach to look for signs that the “blood-brain barrier” is breaking down in people with drug-resistant epilepsy. It may help researchers understand what is happening in the brain and guide future treatments, though it is primarily a testing/study study.
Bethesda, MarylandAges 18–60 - NCT07399327Recruiting
SEEG thermocoagulation for hard-to-treat epilepsy
This study is looking at how well a procedure called SEEG thermocoagulation (a way to stop seizures by heating a small area of brain tissue) works for people with epilepsy that doesn't improve with medication. By joining, you will help doctors understand why this treatment works for some people and not others.
MarseilleAges 12 years+ - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT07605858Recruiting
Epilepsy, Sleep, and Brain Activity Study
This study examines how seizures affect sleep quality and dreams in people with hard-to-treat focal epilepsy. Researchers will use specialized brain electrodes to understand these connections during sleep, which may help improve treatment in the future.
Durham, North CarolinaAges 18–55 - NCT04260477RecruitingPhase 3
Testing a new stronger TB retreatment medicine schedule
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
NiameyAges Any age - NCT04934228RecruitingPhase 1
Study targeting inflammation in people with obesity and high blood pressure
This Phase 1 study looks at a treatment aimed at reducing “inflammation patterns” that are common in obesity and insulin resistance. If you meet specific health and lab criteria, you may be asked to visit a research lab and provide blood samples to see how the treatment affects your body.
Kansas City, KansasAges 18–79 - NCT07592195Recruiting
Breathing and aerobic exercise for men in drug recovery
This study tests whether breathing exercises and aerobic exercise (like walking or jogging) improve physical and mental health in men recovering from substance use. You'd attend supervised exercise sessions twice a week for 8 weeks and complete health questionnaires.
LuzhouAges 18–50 - NCT06806345RecruitingPhase 1/Phase 2
Oxygen therapy for insulin resistance after menopause
This trial tests whether hyperbaric oxygen therapy can help reduce insulin resistance in postmenopausal women. It may offer a new way to improve blood sugar control.
Cairo, Cairo GovernorateAges 55–65 - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT03591276RecruitingPhase 1/Phase 2
Doxorubicin plus pembrolizumab for hormone-resistant breast cancer
This Phase 1b/2 trial tests a combination of pegylated liposomal doxorubicin and pembrolizumab for breast cancer that no longer responds to hormone treatment. It aims to see how well the combination works and how safely it can be given to patients with advanced disease.
JerusalemAges 18 years+ - NCT06434610RecruitingPhase 2
Study of B013 plus paclitaxel for ovarian cancer
This study tests a new drug (B013) combined with a standard chemotherapy (paclitaxel) for people with ovarian cancer that has come back after platinum-based treatment. The goal is to see if the combination works better than the current options.
BeijingAges 18–75 - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Little Rock, ArkansasAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT06511908RecruitingPhase 2
Testing a new ketamine-like drug for hard-to-treat depression
This study tests a new experimental drug (2R,6R)-HNK, a chemical related to ketamine, given by IV infusion to see if it can help people with depression that hasn't improved with other treatments. The goal is to find a new option for people who have not found relief from standard antidepressants.
Bethesda, MarylandAges 18–70 - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Anchorage, AlaskaAges 18 years+ - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Charlotte, North CarolinaAges 18 years+ - NCT03973268RecruitingPhase 1
Ketamine study to understand treatment response in hard-to-treat depression
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
Bethesda, MarylandAges 18–70 - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT06462196Recruiting
Study of Depression, Bipolar Disorder & Suicide Risk
This study looks at how depression, bipolar disorder, and suicide risk naturally change over time. It aims to better understand these conditions so doctors can improve treatments.
Bethesda, MarylandAges 18–120 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+
Hear when a new Drug Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for drug resistance?
- Yes. Clin2 currently lists 122 recruiting drug resistance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a drug resistance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a drug resistance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.